These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18326328)

  • 1. [Development trend in new therapeutic approaches for anemia].
    Ohyashiki K
    Nihon Rinsho; 2008 Mar; 66(3):569-74. PubMed ID: 18326328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
    Greenberg PL; Cosler LE; Ferro SA; Lyman GH
    J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Darbepoetin alfa for anemia with myelodysplastic syndrome.
    Seastone DJ; Gerds AT
    Expert Rev Hematol; 2015 Apr; 8(2):139-46. PubMed ID: 25579702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
    Kelaidi C; Fenaux P
    Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing anemia in patients with chronic kidney disease or cancer: development and role of darbepoetin alfa.
    Scott SD
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):129S-132S. PubMed ID: 12222582
    [No Abstract]   [Full Text] [Related]  

  • 7. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa.
    Valley AW
    Pharmacotherapy; 2002 Sep; 22(9 Pt 2):150S-159S. PubMed ID: 12222585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoiesis-stimulating agents in the treatment of cancer-associated anemia.
    Bohlius J; Engert A; Schwarzer G
    JAMA; 2008 Dec; 300(24):2854-5; author reply 2855-7. PubMed ID: 19109112
    [No Abstract]   [Full Text] [Related]  

  • 9. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
    List AF; Baker AF; Green S; Bellamy W
    Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical use of erythropoietic stimulating agents in myelodysplastic syndromes.
    Santini V
    Oncologist; 2011; 16 Suppl 3():35-42. PubMed ID: 21930833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.
    Moyo V; Lefebvre P; Duh MS; Yektashenas B; Mundle S
    Ann Hematol; 2008 Jul; 87(7):527-36. PubMed ID: 18351340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk-based management of myelodysplastic syndrome.
    Steensma DP; Tefferi A
    Oncology (Williston Park); 2007 Jan; 21(1):43-54; discussion 57-8, 62. PubMed ID: 17313156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of the association of lenalidomide to erythropoiesis-stimulating agents in del (5q) MDS patients refractory to single-agent lenalidomide.
    Park S; Vassilieff D; Bardet V; Viguié F; Dreyfus F
    Leukemia; 2010 Nov; 24(11):1960-2. PubMed ID: 20724986
    [No Abstract]   [Full Text] [Related]  

  • 15. Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson.
    Glaspy JA
    Oncology (Williston Park); 2011 Apr; 25(5):423-4. PubMed ID: 21710839
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythropoietin in kidney disease and type 2 diabetes.
    Schnuelle P; Benck U; Krämer BK
    N Engl J Med; 2011 Jan; 364(4):384; author reply 385-6. PubMed ID: 21268746
    [No Abstract]   [Full Text] [Related]  

  • 17. Erythropoietin in kidney disease and type 2 diabetes.
    Thum T; Kalantar-Zadeh K; Anker SD
    N Engl J Med; 2011 Jan; 364(4):384-5; author reply 385-6. PubMed ID: 21268744
    [No Abstract]   [Full Text] [Related]  

  • 18. Darbepoetin alfa for anemia in patients with low or intermediate-1 risk myelodysplastic syndromes and positive predictive factors of response.
    Villegas A; Arrizabalaga B; Fernández-Lago C; Castro M; Mayans JR; González-Porras JR; Duarte RF; Remacha AF; Luño E; Gasquet JA
    Curr Med Res Opin; 2011 May; 27(5):951-60. PubMed ID: 21381892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolving applications of lenalidomide in the management of anemia in myelodysplastic syndromes.
    List AF
    Cancer Control; 2006 Dec; 13 Suppl():12-6. PubMed ID: 17242662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of anemia in myelodysplastic syndrome with darbepoetin and granulocyte colony stimulating factor.
    Rose S; Ali Y; Maffei B; Saidi P
    Am J Hematol; 2007 Mar; 82(3):245-6. PubMed ID: 16924646
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.